Please wait while the formulary information is being retrieved.
MEGESTROL ACETATE (MEGESTROL ACETATE)
- Anorexia from HIV
- Cachexia due to HIV
- Weight loss due to HIV
- Endometrial carcinoma
- Hormone receptor positive breast cancer
- Megestrol Tablet
- Megestrol Tab
- Megestrol Oral Suspension
- Megestrol Oral Susp
- Megace Es Oral Suspension
- By Indication
megestrol 20 mg tablet
- 1 tablet (20 mg) by oral route 4 times per day
megestrol 40 mg tablet
- 1 tablet (40 mg) by oral route 2 times per day
20 mg tablet
- 1 tablet (20 mg) by oral route 4 times per day
40 mg tablet
- 1 tablet (40 mg) by oral route 2 times per day
megestrol 400 mg/10 mL (10 mL) oral suspension
- 10 milliliters (400 mg) by oral route once daily
megestrol 400 mg/10 mL (40 mg/mL) oral suspension
- 10 milliliters (400 mg) by oral route once daily
megestrol 625 mg/5 mL oral suspension
- 5 milliliters (625 mg) by oral route every 24 hours
megestrol 800 mg/20 mL (20 mL) oral suspension
- 20 milliliters (800 mg) by oral route once daily
400 mg/10 mL (10 mL) oral suspension
- 10 milliliters (400 mg) by oral route once daily
400 mg/10 mL (40 mg/mL) oral suspension
- 10 milliliters (400 mg) by oral route once daily
625 mg/5 mL oral suspension
- 5 milliliters (625 mg) by oral route every 24 hours
800 mg/20 mL (20 mL) oral suspension
- 20 milliliters (800 mg) by oral route once daily
625 mg/5 mL oral suspension
- 5 milliliters (625 mg) by oral route every 24 hours
Anorexia from HIV
- 10 milliliters (400 mg) by oral route once daily
- 5 milliliters (625 mg) by oral route every 24 hours
- 5 milliliters (625 mg) by oral route once daily
- 20 milliliters (800 mg) by oral route once daily
Cachexia due to HIV
- 10 milliliters (400 mg) by oral route once daily
- 5 milliliters (625 mg) by oral route every 24 hours
- 5 milliliters (625 mg) by oral route once daily
- 20 milliliters (800 mg) by oral route once daily
Endometrial carcinoma
- 1 tablet (20 mg) by oral route 3 times per day
- 1 tablet (20 mg) by oral route 2 times per day
- 1 tablet (20 mg) by oral route 4 times per day
- 2 tablets (40 mg) by oral route 4 times per day
- 1 tablet (40 mg) by oral route 4 times per day
- 2 tablets (40 mg) by oral route 2 times per day
- 1 tablet (40 mg) by oral route 2 times per day
- 2 tablets (40 mg) by oral route 3 times per day
- 1 tablet (40 mg) by oral route 3 times per day
- 2 tablets (80 mg) by oral route 3 times per day
- 2 tablets (80 mg) by oral route 4 times per day
- 2 tablets (80 mg) by oral route 2 times per day
Hormone receptor positive breast cancer
- 2 tablets (40 mg) by oral route 4 times per day
- 1 tablet (40 mg) by oral route 4 times per day
Weight loss due to HIV
- 10 milliliters (400 mg) by oral route once daily
- 5 milliliters (625 mg) by oral route every 24 hours
- 5 milliliters (625 mg) by oral route once daily
- 20 milliliters (800 mg) by oral route once daily
- dofetilide
- natalizumab
- Tikosyn
- Tysabri
Contraindicated
- None
Severe
Moderate
- None
- Pregnancy
Contraindicated
- Adrenal cortical insufficiency
Severe
Moderate
- Chronic heart failure
- Diabetes mellitus
- Hypertension
- Thromboembolic disorder
MEGESTROL ACETATE (MEGESTROL ACETATE)
- Anorexia from HIV
- Cachexia due to HIV
- Weight loss due to HIV
- Endometrial carcinoma
- Hormone receptor positive breast cancer
- Hypertension
- Skin rash
- Diarrhea
- Erectile dysfunction
- Flatulence
- Insomnia
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Anemia
- Bullous dermatitis
- Acute confusion
- Candidiasis
- Constipation
- Dyspepsia
- Fever
- General weakness
- Headache disorder
- Increased urinary frequency
- Infection
- Libido changes
- Sialorrhea
- Urinary tract infection
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal glucose tolerance
- Adrenal cortical insufficiency
- Altered mental status
- Cardiomyopathy
- Chest pain
- Deep venous thrombosis
- Depression
- Diabetes mellitus
- Dyspnea
- Edema
- Hepatomegaly
- Hyperglycemia
- Leukopenia
- Peripheral edema
- Pulmonary thromboembolism
- Seizure disorder
- Thrombophlebitis
Less Severe
- Abnormal vaginal bleeding
- Acute abdominal pain
- Alopecia
- Amblyopia
- Cough
- Disturbance in thinking
- Gynecomastia
- Hyperhidrosis
- Hypesthesia
- Pain
- Palpitations
- Paresthesia
- Peripheral sensory neuropathy
- Pharyngitis
- Pruritus of skin
- Urinary incontinence
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Megestrol
Risk of adrenal insufficiency with chronic use. Safety and efficacy not established.
- 1 Day – 18 Years
- Risk of adrenal insufficiency with chronic use. Safety and efficacy not established.
Megestrol Acetate
- Severity Level:
1
- Additional Notes: Insufficient human data; animal data suggest developmental toxicity.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Megestrol
caution; potential for adverse effect on infant, mfr does not recommend
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | caution; potential for adverse effect on infant, mfr does not recommend |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
Megestrol (appetite Stimulant)
Cardiovascular-Avoid use in the elderly. Increased thrombotic event risk. Renal-Primarily renally excreted which may further increase ADR risks in elderly. General- Little evidence to support use for weight gain. May induce vaginal bleeding in females.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | N | N |
BEERS: Y HEDIS: Y STOPP: Y
Precaution Exists
Megestrol (antineoplastic)
Cardiovascular-Increased risk of thrombosis. Caution with history of thromboembolism. Renal-ADR risk may be increased due to reduced renal function. General- May induce hot flashes.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | N | N | N |
BEERS: N HEDIS: Y STOPP: N
No Known Risk
None
- None
| Anorexia from HIV | |
| R63.0 | Anorexia |
| Cachexia due to HIV | |
| R64 | Cachexia |
| Endometrial carcinoma | |
| C54.1 | Malignant neoplasm of endometrium |
| Hormone receptor positive breast cancer | |
| C50 | Malignant neoplasm of breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.12 | Malignant neoplasm of central portion of breast, male |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.22 | Malignant neoplasm of upper-inner quadrant of breast, male |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.32 | Malignant neoplasm of lower-inner quadrant of breast, male |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.42 | Malignant neoplasm of upper-outer quadrant of breast, male |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.52 | Malignant neoplasm of lower-outer quadrant of breast, male |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.62 | Malignant neoplasm of axillary tail of breast, male |
| C50.621 | Malignant neoplasm of axillary tail of right male breast |
| C50.622 | Malignant neoplasm of axillary tail of left male breast |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.82 | Malignant neoplasm of overlapping sites of breast, male |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| C50.92 | Malignant neoplasm of breast of unspecified site, male |
| C50.921 | Malignant neoplasm of unspecified site of right male breast |
| C50.922 | Malignant neoplasm of unspecified site of left male breast |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast |
| Z17.0 | Estrogen receptor positive status [Er+] |
| Z19.1 | Hormone sensitive malignancy status |
| Weight loss due to HIV | |
| R63.4 | Abnormal weight loss |
| 0-9 | A-Z |
|---|---|
| C50 | Malignant neoplasm of breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.12 | Malignant neoplasm of central portion of breast, male |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.22 | Malignant neoplasm of upper-inner quadrant of breast, male |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.32 | Malignant neoplasm of lower-inner quadrant of breast, male |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.42 | Malignant neoplasm of upper-outer quadrant of breast, male |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.52 | Malignant neoplasm of lower-outer quadrant of breast, male |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.62 | Malignant neoplasm of axillary tail of breast, male |
| C50.621 | Malignant neoplasm of axillary tail of right male breast |
| C50.622 | Malignant neoplasm of axillary tail of left male breast |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.82 | Malignant neoplasm of overlapping sites of breast, male |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| C50.92 | Malignant neoplasm of breast of unspecified site, male |
| C50.921 | Malignant neoplasm of unspecified site of right male breast |
| C50.922 | Malignant neoplasm of unspecified site of left male breast |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast |
| C54.1 | Malignant neoplasm of endometrium |
| R63.0 | Anorexia |
| R63.4 | Abnormal weight loss |
| R64 | Cachexia |
| Z17.0 | Estrogen receptor positive status [Er+] |
| Z19.1 | Hormone sensitive malignancy status |
Formulary Reference Tool